Moreover, cabozantinib, a receptor tyrosine kinase inhibitor that can inhibit osteoclast differentiation and resorption, modulates RANKL/osteoprotegerin in osteoblast, found to be well tolerated in AML and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation [146]. Here, TNFSF11 is linked to acute myeloid leukemia.